PANACEA BIOTEC LTD. - 531349 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Vinod GoelDesignation :- Company Secretary and Compliance Officer
Breaking News: DCGI approves emergency use of Russian vaccine Sputnik V
India is the leading production hub for Sputnik V. RDIF has signed pacts with Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech to produce over 850 million doses per yearCovid-19 vaccine: Panacea Biotec to begin Sputnik V manufacturing within 90 days
New Delhi-based firm likely to announce in two weeks PANACEA BIOTEC LTD. - 531349 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Reg.: Issue of Duplicate Share Certificate Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed details pertaining to issuance of duplicate share certificate to the shareholder consequent to loss of share certificate being reported by the shareholder. This is for your information and record please. PANACEA BIOTEC LTD. - 531349 - Clarification On News Item Appearing In 'Economictimes.Indiatimes.Com' Captioned 'Panacea In Talks With Bharat Biotech To Make Covaxin'
With reference to the captioned subject, we would like to state as under: 1. As a policy, the Company does not comment on media speculation and rumours and cannot confirm or deny any transaction which may or may not be in the works. Our Company evaluates various opportunities on an ongoing basis. 2. We have made and will continue to make necessary disclosures in compliance with our obligations under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. You are requested to take the same on records. PANACEA BIOTEC LTD. - 531349 - Clarification sought from Panacea Biotec Ltd
The Exchange has sought clarification from Panacea Biotec Ltd on April 8, 2021, with reference to news appeared in economictimes.indiatimes.com dated April 8, 2021 quoting "Panacea in talks with Bharat Biotech to make Covaxin".The reply is awaited. PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
This is with reference to CDSL's Operating Instructions for Issuers/RTAs, which states that the Issuer/RTA shall inform the details of the securities dematerialized to all the Stock Exchanges where the securities are listed. Accordingly, we would like to inform you that no share has been dematerialized during the month of March, 2021. PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith a certificate dated April 02, 2021, issued by Skyline Financial Services Private Limited, Registrar and Transfer Agent of the Company, confirming compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2021.Panacea Biotec shares zoom 20%; hit upper circuit
Shares of Panacea Biotec on Tuesday rallied 20 per cent after the Russian Direct Investment Fund (RDIF) and the drug firm agreed to produce 100 millio PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Panacea Biotec Ltd. ('PBL') is delighted to announce that the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) and Panacea Biotec, one of the leading vaccine and pharmaceutical producers in India, has agreed for cooperation to produce 100 million doses per year of Sputnik V, the world's first registered vaccine against coronavirus. A copy of the Press Release titled 'RDIF and Panacea Biotec agree to produce 100 million doses of Sputnik V vaccine in India per year' being issued to the media, etc. in this regard is enclosed for your kind reference and record please.